| Literature DB >> 26664994 |
Aruna Shrestha1, Ahmed Abd-Elfattah1, Barbara Freudenschuss1, Barbara Hinney1, Nicola Palmieri1, Bärbel Ruttkowski1, Anja Joachim1.
Abstract
Cystoisospora suis is a coccidian species that typically affects suckling piglets. Infections occur by oral uptake of oocysts and are characterized by non-hemorrhagic transient diarrhea, resulting in poor weight gain. Apparently, primary immune responses to C. suis cannot readily be mounted by neonates, which contributes to the establishment and rapid development of the parasite, while in older pigs age-resistance prevents disease development. However, the presence of extraintestinal stages, although not unequivocally demonstrated, is suspected to enable parasite persistence together with the induction and maintenance of immune response in older pigs, which in turn may facilitate the transfer of C. suis-specific factors from sow to offspring. It is assumed that neonates are particularly prone to clinical disease because infections with C. suis interfere with the establishment of the gut microbiome. Clostridia have been especially inferred to profit from the altered intestinal environment during parasite infection. New tools, particularly in the area of genomics, might illustrate the interactions between C. suis and its host and pave the way for the development of new control methods not only for porcine cystoisosporosis but also for other mammalian Cystoisospora infections. The first reference genome for C. suis is under way and will be a fertile ground to discover new drugs and vaccines. At the same time, the establishment and refinement of an in vivo model and an in vitro culture system, supporting the complete life cycle of C. suis, will underpin the functional characterization of the parasite and shed light on its biology and control.Entities:
Keywords: Cystoisospora suis; coccidian; immunology; microbiome; piglets; swine
Year: 2015 PMID: 26664994 PMCID: PMC4672278 DOI: 10.3389/fvets.2015.00068
Source DB: PubMed Journal: Front Vet Sci ISSN: 2297-1769
Figure 1Proposed model of . (A) Oocysts are excreted with feces and undergo sporulation in the environment. (B) Sporulated oocysts excyst upon ingested by host to release sporozoites. (C) Sporozoites invade intestinal epithelium and develop to become merozoites (1). In contrast to Eimeria, merogony in C. suis is not synchronized but rather stages are defined as types (2–3). It is currently not known which type could act as extraintestinal resting stage. (D) Merogony is followed by gamogony resulting in fusion of macro- and micro-gametes to form a zygote and subsequently an oocyst. (E) The desynchronization of the merogonic development may also be responsible for the characteristic oocyst excretion occurring in two (or more) peaks, when some of the merozoites may undergo rapid development to gamogonic stages, while others enter into a development lag phase to undergo the sexual maturation for the next peak. (F) In response to infection, naïve B cells proliferate and produce IgA, IgG, and IgM. (G) Intake of colostrum and milk, rich in antibodies and cellular components could partially confer passive humoral immunity against C. suis from sow to piglets. (H) Following infection, TCR-γδ T cells show an almost 30-fold increase in the epithelium and are assumed to be the major producers of IFN-γ, which could support the termination of primary infection in pigs harboring sufficient numbers of these cells in the gut, which is age dependent. (I) The existence of extraintestinal stages of C. suis in liver and spleen of adult pig has been proposed, but viable stages in these tissues have not been demonstrated yet.
Figure 2Schematic view of the . The genome sequence can be assembled with next generation sequencing using a combination of short and long reads libraries. Tools such as CLC (CLC Bio-Qiagen, Aarhus, Denmark), Maker (88), and Blast2GO (70) can be applied for de novo assembly, annotation, and functional annotation, respectively. Other NGS technologies, such as RNA-Seq (89) and CHIP-Seq (90), together with proteomics (91), can be used to unravel the biology of the parasite and to discover new drugs and vaccines. Changes involved in host–parasite interaction (A) and developmental switches (B) can be identified both at the genetic and epigenetic level by RNA-Seq and CHIP-Seq, respectively: transcripts are reconstructed using the programs TopHat (92) and Cufflinks (93); differentially expressed genes are detected by edgeR (94); CHIP-Seq data are processed with the MACS software (95). (C) 3D structure of drug candidates can be reconstructed by homology using Swiss-Model (96); screening of virtual libraries of compounds can be performed with AutoDock (97). (D) Vaccine candidates can be identified using Vacceed (86) and validated by proteomics approaches, such as mass spectrometry, with the aid of the software PEAKS (Bioinformatics Solutions Inc., Waterloo, ON, Canada).